Biondo Investment Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.99M | Buy |
11,210
+318
| +3% | +$216K | 0.86% | 36 |
|
|
2026
Q1 | $8.42M | Buy |
10,892
+219
| +2% | +$168K | 1.08% | 33 |
|
|
2025
Q4 | $8.24M | Buy |
10,673
+2,409
| +29% | +$1.64M | 1% | 35 |
|
|
2025
Q3 | $4.65M | Sell |
8,264
-237
| -3% | -$134K | 0.58% | 41 |
|
|
2025
Q2 | $4.46M | Buy |
8,501
+40
| +0.5% | +$22.3K | 0.59% | 42 |
|
|
2025
Q1 | $5.37M | Buy |
8,461
+7,586
| +867% | +$5.22M | 0.76% | 40 |
|
|
2024
Q4 | $623K | Sell |
875
-30
| -3% | -$25.2K | 0.09% | 69 |
|
|
2024
Q3 | $951K | Hold |
905
| – | – | 0.13% | 66 |
|
|
2024
Q2 | $951K | Hold |
905
| – | – | 0.14% | 65 |
|
|
2024
Q1 | $871K | Hold |
905
| – | – | 0.13% | 65 |
|
|
2023
Q4 | $795K | Buy |
905
+50
| +6% | +$41.2K | 0.14% | 66 |
|
|
2023
Q3 | $704K | Sell |
855
-150
| -15% | -$118K | 0.13% | 67 |
|
|
2023
Q2 | $722K | Hold |
1,005
| – | – | 0.13% | 66 |
|
|
2023
Q1 | $826K | Buy |
1,005
+125
| +14% | +$94.3K | 0.17% | 64 |
|
|
2022
Q4 | $635K | Sell |
880
-25
| -3% | -$18.4K | 0.14% | 65 |
|
|
2022
Q3 | $623K | Hold |
905
| – | – | 0.14% | 66 |
|
|
2022
Q2 | $535K | Sell |
905
-337
| -27% | -$219K | 0.12% | 67 |
|
|
2022
Q1 | $867K | Buy |
1,242
+337
| +37% | +$213K | 0.15% | 68 |
|
|
2021
Q4 | $572K | Hold |
905
| – | – | 0.1% | 73 |
|
|
2021
Q3 | $548K | Buy |
905
+485
| +115% | +$301K | 0.09% | 71 |
|
|
2021
Q2 | $235K | Buy |
+420
| New | +$213K | 0.04% | 81 |
|
|
2020
Q4 | – | Sell |
-3,350
| Closed | -$1.88M | – | 87 |
|
|
2020
Q3 | $1.88M | Hold |
3,350
| – | – | 0.41% | 44 |
|
|
2020
Q2 | $2.09M | Buy |
+3,350
| New | +$1.9M | 0.53% | 43 |
|
|
2019
Q3 | – | Sell |
-1,050
| Closed | -$329K | – | 89 |
|
|
2019
Q2 | $329K | Sell |
1,050
-23,682
| -96% | -$7.88M | 0.08% | 81 |
|
|
2019
Q1 | $10.2M | Buy |
24,732
+6,980
| +39% | +$2.87M | 2.55% | 10 |
|
|
2018
Q4 | $6.63M | Sell |
17,752
-8,160
| -31% | -$2.99M | 2% | 14 |
|
|
2018
Q3 | $10.5M | Buy |
25,912
+9,070
| +54% | +$3.45M | 2.49% | 11 |
|
|
2018
Q2 | $5.81M | Buy |
16,842
+408
| +2% | +$128K | 1.47% | 22 |
|
|
2018
Q1 | $5.66M | Buy |
16,434
+282
| +2% | +$98.1K | 1.47% | 23 |
|
|
2017
Q4 | $6.07M | Sell |
16,152
-73
| -0.4% | -$29.6K | 1.53% | 21 |
|
|
2017
Q3 | $7.25M | Buy |
16,225
+740
| +5% | +$352K | 2% | 15 |
|
|
2017
Q2 | $7.61M | Buy |
15,485
+13,200
| +578% | +$5.78M | 2.2% | 13 |
|
|
2017
Q1 | $798K | Sell |
2,285
-9,650
| -81% | -$3.58M | 0.29% | 53 |
|
|
2016
Q4 | $4.38M | Buy |
11,935
+465
| +4% | +$177K | 1.45% | 21 |
|
|
2016
Q3 | $4.61M | Buy |
11,470
+9,185
| +402% | +$3.68M | 1.56% | 20 |
|
|
2016
Q2 | $798K | Buy |
2,285
+935
| +69% | +$360K | 0.28% | 53 |
|
|
2016
Q1 | $487K | Buy |
+1,350
| New | +$556K | 0.18% | 59 |
|
Other funds holding REGN
Biondo Investment Advisors's REGN Position: Q2 2026 in Review
Biondo Investment Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 2.9% in Q2 2026, buying an estimated $216K and bringing the position to 11,210 shares worth $6.99M. The position accounts for 0.86% of the portfolio, ranked #36.
Biondo Investment Advisors first reported a position in REGN in Q1 2016 and has held it in 37 quarters since. The position peaked at $10.5M in Q3 2018. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Biondo Investment Advisors held 11,210 shares of Regeneron Pharmaceuticals worth $6.99M as of Q2 2026.
- Biondo Investment Advisors bought 318 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $216K.
- Regeneron Pharmaceuticals made up 0.86% of Biondo Investment Advisors's portfolio in Q2 2026, its #36 holding.
- Biondo Investment Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2016 and has held it in 37 quarters since.
- Biondo Investment Advisors's Regeneron Pharmaceuticals position peaked at $10.5M in Q3 2018.
- 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Biondo Investment Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.